<DOC>
	<DOCNO>NCT02439216</DOCNO>
	<brief_summary>The MoveDMD study 3-part , Phase 1/2 , multi-site study evaluate safety , efficacy , pharmacokinetics ( PK ) pharmacodynamics ( PD ) CAT-1004 ( know edasalonexent ) pediatric patient genetically confirm diagnosis DMD . Approximately 30 ambulatory , male patient ≥4 &lt; 8 year age enrol overall . Edasalonexent orally administer small molecule target inhibit activated NF-κB , molecule activate infancy DMD central cause muscle damage prevent muscle regeneration . Data magnetic resonance image low upper leg muscle , physical function ( include time function test ) muscle strength study . Part A initiated April 2015 complete . All three dos CAT-1004 test generally well tolerate safety signal observe . The majority adverse event mild , common adverse event gastrointestinal ( primarily diarrhea ) . There serious adverse event drug discontinuation . Part B randomize , double-blind , placebo-controlled , multiple dose study evaluate safety , efficacy , PK , PD edasalonexent 12 week . Patients participate Part A may also participate Part B , along newly enrol patient . Following completion Part B , patient receive CAT-1004 36 week Part C , open-label portion CAT-1004-201 study .</brief_summary>
	<brief_title>Phase 1/2 Study Boys With Duchenne Muscular Dystrophy</brief_title>
	<detailed_description />
	<mesh_term>Muscular Dystrophies</mesh_term>
	<mesh_term>Muscular Dystrophy , Duchenne</mesh_term>
	<criteria>Written inform consent parent legal guardian prior participation , patient 7 year age , write assent patient Diagnosis DMD base clinical phenotype increase serum CK presence mutation dystrophin gene know associate DMD phenotype Ability walk independently ( assistive device permit ) Adequate immunization influenza varicella Use corticosteroid within prior 6 month treatment initiation plan initiate steroid therapy within next 6 month Other prior ongoing significant medical condition Exposure another investigational drug ( eteplirsen idebenone ) within 28 day prior start study treatment ongoing participation therapeutic clinical trial Note : There separate criterion patient participate Part A versus newly enrol patient . New patient must meet Part A entry criterion participate Part B . Patients participate Part A must meet follow criterion participate Part B : Completed Part A Continue meet Part A entry criterion , include absence safety concern ( however , patient may ≥8 year age ) There entry criterion Part C ; patient complete Part B automatically continue Part C</criteria>
	<gender>Male</gender>
	<minimum_age>4 Years</minimum_age>
	<maximum_age>7 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Muscular Dystrophies</keyword>
	<keyword>Musculoskeletal Diseases</keyword>
	<keyword>Nervous System Diseases</keyword>
	<keyword>Neuromuscular Diseases</keyword>
	<keyword>Duchenne muscular dystrophy</keyword>
	<keyword>DMD</keyword>
	<keyword>dystrophin</keyword>
	<keyword>dystrophy</keyword>
	<keyword>Duchenne</keyword>
</DOC>